Managing behavioral health in persons withdementia is an enormous and growing problem. Most patients with Alzheimer's disease (AD) have challengingneuropsychiatric symptoms such as agitation. These symptoms are distressing andoften overwhelming for caregivers often resulting in institutionalization andincreased healthcare utilization. Several medications are used off-labelto treat these symptoms including antidepressants, antipsychotics,anticonvulsants, anxiolytics and cholinesterase inhibitors. But manyregulatory bodies, professional associations, and patient advocacy groups havepromoted initiatives to decrease the inappropriate use of medications andencourage the use of alternatives, particularly behavioral interventions. The combination of dextromethorphan hydrobromideand quinidine sulfate (Nuedexta) has been recently studied for the off-labeltreatment of agitation in Alzheimer’s disease. A patient-centered, systematic, andevidence-based approach should be considered when addressing the behavioral and psychological symptoms of dementia.
Powerful Placebos and Notorious Nocebos: Implications for Ambulatory Care
An Incli-ng of Benefit? Efficacy and Safety of Inclisiran for Elevated LDL
Will Riva Be Defeated By It’s (Long-Standing) Nemesis, Apixa?
Should Penicillin Allergy Skin Testing be a Thing of the PAST?
Does Long-Term Proton Pump Inhibitor Use Pump Up Your Risk of Adverse Effects?
Is the Grass Really Greener? Cognitive Function After Discontinuation of Cannabis
A CLEAN Sweep: Getting Rid of the Medication Cost Barrier
Should Bedtime be Med-Time for Hypertension?
Let’s COLCOT to the Chase: Colchicine for Secondary Prevention of CV Events
Don’t Let Numbers Fool You: Levothyroxine Isn’t a Cure-all
Age is Just a Number: Discontinue Statins with Care
A Cause for a PAUSE: Evaluating a Standardized Perioperative DOAC Management Protocol
Who CARES? Getting to the Heart of Allopurinol and Febuxostat CV Outcomes
Up in Flames: Antiplatelet Therapy in Patients with Stable Ischemic Heart Disease Receiving Anticoagulation for A-fib
Is Dapagliflozin aDAPtAble to Treating HFrEF in Patients Without Diabetes?
Are Older Adults with Heart Failure Self-Care Aware?
Secondary Stroke Prevention in A-Fib: Do DOACs PROSPER in High-Risk Patients?
Under Pressure: Does Directly Observing Medication Administration Lower Blood Pressure?
Will Oral Semaglutide PIONEER the Way to Lower Cardiovascular Risk?
Using CRP in COPD to Guide Treatment Decisions During Exacerbations
Create your
podcast in
minutes
It is Free
Good Mood Revolution
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
Precision Medicine Forum Podcast
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive